Expanding antigen-specific regulatory networks to treat autoimmunity

Xavier Clemente-Casares, Jesus Blanco, Poornima Ambalavanan, Jun Yamanouchi, Santiswarup Singha, Cesar Fandos, Sue Tsai, Jinguo Wang, Nahir Garabatos, Cristina Izquierdo, Smriti Agrawal, Michael B. Keough, V. Wee Yong, Eddie James, Anna Moore, Yang Yang, Thomas Stratmann, Pau Serra and Pere Santamaria ()
Additional contact information
Xavier Clemente-Casares: Julia McFarlane Diabetes Research Centre (JMDRC), Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary
Jesus Blanco: Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Poornima Ambalavanan: Julia McFarlane Diabetes Research Centre (JMDRC), Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary
Jun Yamanouchi: Julia McFarlane Diabetes Research Centre (JMDRC), Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary
Santiswarup Singha: Julia McFarlane Diabetes Research Centre (JMDRC), Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary
Cesar Fandos: Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Sue Tsai: Julia McFarlane Diabetes Research Centre (JMDRC), Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary
Jinguo Wang: Julia McFarlane Diabetes Research Centre (JMDRC), Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary
Nahir Garabatos: Faculty of Biology, University of Barcelona
Cristina Izquierdo: Faculty of Biology, University of Barcelona
Smriti Agrawal: Faculty of Medicine, University of Calgary
Michael B. Keough: Faculty of Medicine, University of Calgary
V. Wee Yong: Faculty of Medicine, University of Calgary
Eddie James: Benaroya Research Institute at Virginia Mason
Anna Moore: Molecular Imaging Laboratory, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
Yang Yang: Julia McFarlane Diabetes Research Centre (JMDRC), Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary
Thomas Stratmann: Faculty of Biology, University of Barcelona
Pau Serra: Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Pere Santamaria: Julia McFarlane Diabetes Research Centre (JMDRC), Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases and Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary

Nature, 2016, vol. 530, issue 7591, 434-440

Abstract: Abstract Regulatory T cells hold promise as targets for therapeutic intervention in autoimmunity, but approaches capable of expanding antigen-specific regulatory T cells in vivo are currently not available. Here we show that systemic delivery of nanoparticles coated with autoimmune-disease-relevant peptides bound to major histocompatibility complex class II (pMHCII) molecules triggers the generation and expansion of antigen-specific regulatory CD4+ T cell type 1 (TR1)-like cells in different mouse models, including mice humanized with lymphocytes from patients, leading to resolution of established autoimmune phenomena. Ten pMHCII-based nanomedicines show similar biological effects, regardless of genetic background, prevalence of the cognate T-cell population or MHC restriction. These nanomedicines promote the differentiation of disease-primed autoreactive T cells into TR1-like cells, which in turn suppress autoantigen-loaded antigen-presenting cells and drive the differentiation of cognate B cells into disease-suppressing regulatory B cells, without compromising systemic immunity. pMHCII-based nanomedicines thus represent a new class of drugs, potentially useful for treating a broad spectrum of autoimmune conditions in a disease-specific manner.

Date: 2016
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://www.nature.com/articles/nature16962 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:530:y:2016:i:7591:d:10.1038_nature16962

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature16962

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().